As the fourth most commonly diagnosed cancer among women worldwide, cervical cancer places a significant burden on low and middle-income countries. Although China reports lower incidence and mortality rates compared to the global average, the stark contrast in mortality rates with developed nations like the USA and the UK underscores the urgent need for enhanced prevention strategies.
A new perspective (DOI:10.20892/j.issn.2095-3941.2023.0432) published in Cancer Biology & Medicine, March 2024, provides an in-depth look at the escalating rates of cervical cancer in China, particularly highlighting the rise in rural areas.
This critical research emphasizes the effectiveness of the HPV vaccine in combatting cervical cancer and addresses challenges such as vaccine supply constraints, socioeconomic barriers, and vaccine hesitancy. Researchers analyzed data reflecting the effectiveness of the HPV vaccine, which has proven to be a critical tool in reducing cancer rates. However, the introduction of the vaccine in China was delayed compared to other countries, affecting overall vaccination coverage. The study also evaluates the impact of China’s adoption of the WHO’s “90-70-90” strategy—aiming for high vaccination, screening, and treatment rates by 2030. The research outlines the urgent need for a multi-faceted approach that includes boosting vaccine supply, expanding screening programs, and enhancing treatment facilities to address the geographic and economic diversity of the Chinese population.
Dr. Youlin Qiao, the corresponding author of the study, stated, “Our research underscores the critical need for comprehensive cervical cancer control strategies that are tailored to China’s diverse socioeconomic landscape. Achieving the World Health Organization’s (WHO) elimination targets not only requires robust vaccination programs but also widespread screening and effective treatment methodologies.”
This pivotal study not only outlines the current challenges in cervical cancer prevention in China but also charts a strategic path forward to potentially eradicate this disease as a public health issue. With continued efforts and international collaboration, China is poised to meet the WHO’s elimination targets within the next decade, signaling a significant leap forward in global health security.
###
References
DOI
10.20892/j.issn.2095-3941.2023.0432
Original Source URL
https://doi.org/10.20892/j.issn.2095-3941.2023.0432
Funding information
This work was supported by the Bill and Melinda Gates Foundation [Research on Expending Human Papillomavirus (HPV) Vaccination, Grant Number: INV–006373; and Implementation Research around the Pilots of Cervical Cancer Elimination, Grant Number: INV-031449].
About Cancer Biology & Medicine
Cancer Biology & Medicine（CBM） is a peer-reviewed open-access journal sponsored by China Anti-cancer Association (CACA) and Tianjin Medical University Cancer Institute & Hospital. The journal monthly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The journal is indexed in SCOPUS, MEDLINE and SCI (IF 5.6, 5 year IF 5.9), with all full texts freely visible to clinicians and researchers all over the world (http://www.ncbi.nlm.nih.gov/pmc/journals/2000/).
